Physician profile
Thomas Bolig
NPI 1962996785
$952.70
in general payments reported to CMS, 2019-2025
15 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $29.16 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.84 | 2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $150.15 | 2025 | Nucala, Trelegy Ellipta |
| Baxter Healthcare | $95.93 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $95.87 | 2025 | |
| United Therapeutics Corporation | $84.60 | 2025 | Tyvaso |
| Harmony Biosciences LLC | $68.71 | 2025 | |
| Genzyme Corporation | $63.61 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.28 | 2025 | |
| Insmed, INC. | $32.40 | 2025 | Brinsupri, Arikayce |
| Astrazeneca Pharmaceuticals LP | $31.40 | 2025 | Fasenra, Airsupra |
| Sandoz INC. | $29.16 | 2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $20.33 | 2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $18.45 | 2025 | Lumryz |
| Amgen INC. | $15.67 | 2025 | Tezspire |
| Grifols USA, LLC | $15.30 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bolig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.